Entrada Therapeutics Inc. is a biotechnology company that focuses on developing and commercializing innovative therapies for the treatment of rare and devastating diseases. The company was founded in 2018 and is headquartered in Boston, Massachusetts, USA.
Entrada's primary area of focus is on intracellular biologics, which are designed to target and deliver therapeutic molecules inside cells to address diseases caused by malfunctioning intracellular processes. These therapies have the potential to treat a wide range of rare genetic disorders that have been challenging to address using traditional drug delivery methods.
The company's proprietary platform, called Endosomal Escape Vehicle (EEV), enables the efficient delivery of large molecules into cells, overcoming one of the key hurdles in developing intracellular biologics. By leveraging this technology, Entrada aims to develop transformative treatments for patients suffering from severe and underserved genetic diseases.
Entrada's mission is to bring effective therapies to patients suffering from rare diseases and improve their quality of life. The company is dedicated to advancing scientific research and technology to develop novel treatments that address the root causes of these rare genetic disorders. Through strategic collaborations and a strong commitment to scientific excellence, Entrada continues to make significant strides in the field of intracellular biologics and holds the promise of transforming the lives of patients and their families affected by these devastating diseases.